The purpose of this observational, multi-center, retrospective cohort study is to assess treatment patterns of Cuvitru (SCIG) 20 percent (%) and HyQvia (fSCIG) in polish pediatric participants with PID. The study will collect pediatric patient data. These data are gathered and collected during routine clinical care. As this is a non-interventional/observational study, no treatment/pharmacotherapy is provided as part of the study.
Subcutaneous immune globulin (SCIG 20%) and facilitated subcutaneous immunoglobulin (fSCIG) treatment in Polish paediatric patients with primary immunodeficiencies (PID) - retrospective medical chart review study
Study Type
OBSERVATIONAL
Enrollment
96
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Uniwersytecki Szpital Dziecięcy w Krakowie
Krakow, Poland
Instytut "Pomnik - Centrum Zdrowia Dziecka"
Warsaw, Poland
Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego
Wroclaw, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Stanisława Szyszko Śląskiego Uniwersytetu Medycznego w Katowicach
Zabrze, Poland
Number of Doses per Infusion
Time frame: From start of the study upto end of the study (6 months)
Number of Infusion Sites
Time frame: From start of the study upto end of the study (6 months)
Infusion Volume
Time frame: From start of the study upto end of the study (6 months)
Method of Administration
Method of administration in participants will be through pump or rapid push.
Time frame: From start of the study upto end of the study (6 months)
Length of Needle
Length of needle used for infusions will be assessed.
Time frame: From start of the study upto end of the study (6 months)
Assessment of Person who Perform the Infusion
Assessment of person (parent/guardian or self) who performs the infusion will be assessed.
Time frame: From start of the study upto end of the study (6 months)
Type of Pump
Time frame: From start of the study upto end of the study (6 months)
Total Dose per 4 weeks
Total dose administered per 4 weeks data will be assessed.
Time frame: From start of the study upto end of the study (6 months)
Total Infusion Volume per 4 Weeks
Time frame: From start of the study upto end of the study (6 months)
Treatment Interval per 4 Weeks
Time frame: From start of the study upto end of the study (6 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.